Thyrocare Technologies Limited announced strong Q3 FY26 results, with revenue up 18% year-on-year to ₹195.53 crore. Profit After Tax (PAT) surged 47% to ₹27.91 crore. The company processed 49.6 million tests, a 22% increase. Thyrocare was also recognized nationally for diagnostic excellence and onboarded Madhuri Dixit as its brand ambassador.
Financial Performance Highlights
Thyrocare reported consolidated revenue of ₹195.53 crore for Q3 FY26, an increase of 18% year-on-year. This growth was primarily driven by a 20% increase in the Pathology segment.
Consolidated EBITDA grew by 38% year-on-year, while Profit After Tax (PAT) increased by 47% year-on-year to ₹27.91Cr.
Operational Excellence
Thyrocare processed 49.6 million tests in Q3 FY26, marking a 22% year-on-year growth.
The company achieved Six Sigma quality standards, reducing complaints per million tests to 3.2 (down 43% YoY) with ATAT at 3.28 hours.
Segment Performance
In the Pathology business, franchise revenue grew by 12% year-on-year, while partnership revenue, including pharmeasy business, recorded a robust 39% year-on-year growth.
Awards and Recognition
Thyrocare was recognized with two National honors: Best Diagnostic Lab Chain of the Year and Patient-Centric Diagnostic Company of the Year.
Brand Ambassador
Madhuri Dixit was onboarded as the brand ambassador.
Source: BSE
